A 58-year-old man with metastatic pancreatic cancer presents to the palliative care clinic with severe, uncontrolled pain (8/10 on visual analogue scale) despite being on paracetamol 1 g QID and ibuprofen 400 mg TDS for the past 3 weeks. On examination, he appears cachectic but alert and oriented. His respiratory rate is 16/min, oxygen saturation 98% on room air, and blood pressure 128/82 mmHg. The palliative care physician decides to initiate opioid therapy. Which of the following opioids is the most appropriate first-line choice for this patient?

Explanation

## Opioid Selection in Cancer Pain Management **Key Point:** Morphine immediate-release (IR) is the gold-standard first-line opioid for opioid-naïve cancer patients with moderate-to-severe pain. It allows rapid titration to effect and establishes the patient's daily requirement before transitioning to long-acting formulations. ### Rationale for Morphine IR as First-Line 1. **Titration flexibility**: IR formulations allow rapid dose escalation every 24–48 hours based on analgesic response and side effects. 2. **Predictable pharmacokinetics**: Onset within 30 minutes, peak at 60 minutes, duration 4–6 hours — ideal for establishing baseline requirements. 3. **Guideline concordance**: WHO analgesic ladder and international cancer pain guidelines (NCCN, ESMO) recommend morphine IR as the reference standard for opioid initiation in cancer pain. 4. **Cost-effectiveness**: Morphine is widely available and affordable in India. 5. **Transition to long-acting**: Once daily morphine requirement is established (typically after 3–5 days), switch to modified-release morphine or other long-acting agents (e.g., transdermal fentanyl) for convenience and steady-state analgesia. ### Dosing Strategy **High-Yield:** Start with 5–10 mg every 4 hours (6 doses/day = 30–60 mg/day baseline). Increase by 25–50% every 24–48 hours until pain control is achieved or side effects limit further escalation. ## Why Other Options Are Suboptimal | Agent | Limitation in Opioid-Naïve Patient | |-------|------------------------------------| | **Fentanyl transdermal** | Slow onset (12–24 hrs to steady state); cannot be rapidly titrated; risk of overdose if patient is opioid-naïve. Appropriate only *after* morphine IR titration. | | **Methadone** | Long, unpredictable half-life (15–60 hrs); risk of accumulation and delayed toxicity in opioid-naïve patients; requires specialist monitoring. Reserved for opioid-tolerant patients or those with morphine allergy. | | **Buprenorphine** | Partial agonist with ceiling effect on analgesia; less suitable for severe cancer pain. Better for opioid-use disorder or mild–moderate pain. | **Clinical Pearl:** The "equianalgesic dose" concept is crucial: once the patient's 24-hour morphine requirement is known, convert to long-acting formulations using established conversion tables (e.g., morphine 30 mg/day IR ≈ morphine 15 mg/12 hrs modified-release or fentanyl 25 mcg/72 hrs). **Warning:** Never initiate long-acting opioids in opioid-naïve patients — the risk of respiratory depression and death is unacceptably high.